Fennell, D. A., Hill, K., Zhang, M., Poile, C., Ewings, S., Baitei, E. Y., Dzialo, J., Nusrat, N., Rogel, J., Faulkner, D., Ottensmeier, C., Califano, R., Hanna, G. G., Danson, S., Steele, N., Nye, M., Johnson, L., Mallard, K., Lord, J., Middleton, C., Szlosarek, P., Chan, S., Darlison, L., Wells-Jordan, P., Richards, C., Harber, J., Bzura, A., Spicer, J., Pritchard, C., Kamata, T., Hahne, J. C., Jama, M., Hollox, E. J., Lester, J. F., Luo, J., Zhou, Z., Yang, H., Zhou, H., Klampatsa, A., Griffiths, G. O. (2025). Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. Nature Communications. https://doi.org/10.1038/s41467-025-61691-4